BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35170548)

  • 1. Potential applications of prognostic and immunological marker transmembrane serine proteinase 2 in prediction, prevention and personalized treatment of lung cancer.
    Mu B; Zhang R; Pu Y; Yao J; Hu X; Zhao C
    Eur J Cancer Prev; 2023 Jan; 32(1):65-68. PubMed ID: 35170548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneous expression of ACE2, TMPRSS2, and FURIN at single-cell resolution in advanced non-small cell lung cancer.
    Liu Z; Gu X; Li Z; Shan S; Wu F; Ren T
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3563-3573. PubMed ID: 35960376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential
    Lin S; Tian C; Li J; Liu B; Ma T; Chen K; Gong W; Wang JM; Huang J
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33786615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC.
    Fu L; Wang H; Wei D; Wang B; Zhang C; Zhu T; Ma Z; Li Z; Wu Y; Yu G
    PLoS One; 2020; 15(5):e0233283. PubMed ID: 32437446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Li Y; Zheng P; Zhan X
    Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural variations and expression profiles of the SARS-CoV-2 host invasion genes in lung cancer.
    Ilikci Sagkan R; Akin-Bali DF
    J Med Virol; 2020 Nov; 92(11):2637-2647. PubMed ID: 32492203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection.
    Kong Q; Xiang Z; Wu Y; Gu Y; Guo J; Geng F
    Mol Cancer; 2020 Apr; 19(1):80. PubMed ID: 32345328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioinformatics analysis of differentially expressed miRNAs in non-small cell lung cancer.
    Yu H; Pang Z; Li G; Gu T
    J Clin Lab Anal; 2021 Feb; 35(2):e23588. PubMed ID: 32965722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Wang J; Zhan X
    Front Immunol; 2021; 12():752643. PubMed ID: 34887858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
    Yang Y; Wang M; Liu B
    J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
    Hou G; Lu Z; Bi Y; Deng J; Yang X
    Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of TOP2A and ADH1B with lipid levels and prognosis in patients with lung adenocarcinoma and squamous cell carcinoma.
    Yin D; Zhang Y; Li H; Cheng L
    Clin Respir J; 2023 Dec; 17(12):1301-1315. PubMed ID: 37985446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
    Yang K; Wu Y
    BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
    Meng F; Zhang L; Ren Y; Ma Q
    J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Common and distinct patterns of acquired uniparental disomy and homozygous deletions between lung squamous cell carcinomas and lung adenocarcinoma.
    Tuna M; Mills GB; Amos CI
    Neoplasia; 2023 Nov; 45():100932. PubMed ID: 37801862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
    Xu XL; Gong Y; Zhao DP
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood FOLR3 methylation dysregulations and heterogeneity in non-small lung cancer highlight its strong associations with lung squamous carcinoma.
    Qu Y; Zhang X; Qiao R; Di F; Song Y; Wang J; Ji L; Zhang J; Gu W; Fang Y; Han B; Yang R; Dai L; Ouyang S
    Respir Res; 2024 Jan; 25(1):59. PubMed ID: 38273401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiRNA expression profiling in adenocarcinoma and squamous cell lung carcinoma reveals both common and specific deregulated microRNAs.
    Petkova V; Marinova D; Kyurkchiyan S; Stancheva G; Mekov E; Kachakova-Yordanova D; Slavova Y; Kostadinov D; Mitev V; Kaneva R
    Medicine (Baltimore); 2022 Aug; 101(33):e30027. PubMed ID: 35984198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High
    Xie L; Dang Y; Guo J; Sun X; Xie T; Zhang L; Yan Z; Amin H; Guo X
    Genes (Basel); 2019 Jan; 10(1):. PubMed ID: 30634629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.